Valion Bio Appoints Melinda Lackey as General Counsel
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy VBIO?
Valion Bio (VBIO) announced the appointment of Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs. Lackey brings nearly two decades of combined scientific and legal experience across clinical-stage biopharmaceutical development, intellectual property strategy, and Nasdaq public company governance, a profile built for Valion Bio's current phase of growth. Lackey joins from Alaunos Therapeutics (TCRT), where she served as Senior Vice President of Legal & Administration.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VBIO
Wall Street analysts forecast VBIO stock price to rise
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 1.040
Low
Averages
High
Current: 1.040
Low
Averages
High
No data
About VBIO
Valion Bio, Inc., formerly Tivic Health Systems, Inc., is a late-stage immunotherapeutics company. The Company offers Entolimod, which is a drug used to treat acute radiation syndrome (ARS). Entolimod is a toll-like receptor 5 (TLR5) agonist that activates an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. Its pipeline also includes Entolimod to treat neutropenia and lymphocyte exhaustion, as well as Entolasta, an immunologically optimized variant of Entolimod for chronic applications. Its subsidiary, Velocity Bioworks, is a full-service contract development and manufacturing organization (CDMO) that is based in San Antonio, Texas. It offers upstream and downstream process development and optimization; analytical testing, assay development, and qualification; quality control and stability testing; microbial and mammalian expression systems; technology transfer and program management services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Valion Bio Opens New Facility to Enhance Cancer Treatment Capabilities
- Facility Launch: Valion Bio's Velocity Bioworks facility in San Antonio officially opens, marking the activation of the company's vertically integrated manufacturing strategy, which is expected to enhance production capabilities for Entolimod™, addressing the needs of cancer patients and U.S. warfighters.
- Strategic Recognition: The facility's opening was acknowledged by Senator John Cornyn and San Antonio Mayor Gina Ortiz Jones, highlighting its significance in the bioscience economy and national preparedness, which is anticipated to stimulate regional economic growth.
- Successful Tech Transfer: Velocity Bioworks recently completed a successful tech transfer of the Entolimod manufacturing process with incremental scale-up activities to support GMP manufacturing, which is expected to accelerate the product's market entry and enhance competitive positioning.
- Talent Concentration: The new facility employs approximately 45 scientists and engineers, with San Antonio chosen for its convergence of life sciences talent and strategic logistics infrastructure, which is expected to drive further growth in the biopharmaceutical sector.
See More
Valion Bio Secures NIAID Funding to Advance Entolimod Research
- Study Protocol Approval: Valion Bio's agreement with NIAID, valued at up to $7 million, aims to support the Biologics License Application (BLA) for Entolimod™, marking a significant advancement in the acute radiation syndrome (ARS) field.
- Preclinical Research Initiation: The first study protocol will evaluate Entolimod™'s efficacy in partial-body irradiation gastrointestinal acute radiation syndrome, addressing a gap where no FDA-approved drug currently exists, potentially positioning Entolimod™ as the only drug with dual protective capabilities.
- Funding and Knowledge Support: NIAID not only provides funding but also commits to collaborating with Valion Bio during the FDA submission process, significantly reducing project risk and enhancing the likelihood of success through government-backed support.
- Accelerated Clinical Development: Valion Bio plans to redirect the $7 million originally allocated for Entolimod™ towards the clinical development of its second-generation molecule, Entolasta™, demonstrating the company's strategy of advancing multiple research fronts simultaneously, thereby enhancing the overall potential of its commercial pipeline.
See More
Valion Bio Opens New Facility to Enhance Cancer Treatment Capabilities
- Facility Launch: Valion Bio's Velocity Bioworks facility in San Antonio officially opens, marking the activation of the company's vertically integrated manufacturing strategy, which is expected to enhance production capabilities for Entolimod™, addressing the needs of cancer patients and U.S. warfighters.
- Strategic Recognition: The facility's opening was acknowledged by Senator John Cornyn and San Antonio Mayor Gina Ortiz Jones, highlighting its significance in the bioscience economy and national preparedness, which is anticipated to stimulate regional economic growth.
- Successful Tech Transfer: Velocity Bioworks recently completed a successful tech transfer of the Entolimod manufacturing process with incremental scale-up activities to support GMP manufacturing, which is expected to accelerate the product's market entry and enhance competitive positioning.
- Talent Concentration: The new facility employs approximately 45 scientists and engineers, with San Antonio chosen for its convergence of life sciences talent and strategic logistics infrastructure, which is expected to drive further growth in the biopharmaceutical sector.
See More
Valion Bio Secures NIAID Funding to Advance Entolimod Research
- Study Protocol Approval: Valion Bio's agreement with NIAID, valued at up to $7 million, aims to support the Biologics License Application (BLA) for Entolimod™, marking a significant advancement in the acute radiation syndrome (ARS) field.
- Preclinical Research Initiation: The first study protocol will evaluate Entolimod™'s efficacy in partial-body irradiation gastrointestinal acute radiation syndrome, addressing a gap where no FDA-approved drug currently exists, potentially positioning Entolimod™ as the only drug with dual protective capabilities.
- Funding and Knowledge Support: NIAID not only provides funding but also commits to collaborating with Valion Bio during the FDA submission process, significantly reducing project risk and enhancing the likelihood of success through government-backed support.
- Accelerated Clinical Development: Valion Bio plans to redirect the $7 million originally allocated for Entolimod™ towards the clinical development of its second-generation molecule, Entolasta™, demonstrating the company's strategy of advancing multiple research fronts simultaneously, thereby enhancing the overall potential of its commercial pipeline.
See More
